36 results about "Streptococcus pneumoniae bacteria" patented technology

The invention discloses a kit for quickly detecting 15 pneumonia pathogenic bacteria. The kit can detect streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, baumanii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae which cover clinically common pneumonia pathogenic bacteria difficult to culture. 16S rDNA and specific gene sequences corresponding to the pneumonia pathogenic bacteria are detected by combining gene chips with multiple asymmetric PCR reactions, and the categories of the bacteria in a to-be-detected sample are identified in genus and species. The kit makes up for the defect that current clinical detection of pneumonia pathogenic bacteria is not in time or comprehensive and a novel detection means for early diagnosis and early treatment of patients suffering from pneumonia is provided.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.

Provided are a method and a kit for accurately and rapidly detecting ten types of targeting pneumonia bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus aureus. A set of primer pairs directed to their respective target regions contained in the DnaJ gene, etc., of the ten types of pneumonia causative bacteria is designed for the ten bacterial strains and used to amplify gene products. A set of bacterial strain-specific probe pairs is further designed for the ten bacterial strains such that the probe pairs hybridize with the amplification products via sequences in the respective target regions differing from the sequences hybridized by the set of primer pairs. A first probe-bound labeled high molecular carrier in which plural types of first probes for the pneumonia bacteria are bound to a labeled high molecular carrier and a solid-phase second probe-carrying developing support are used as the set of probe pairs to perform nucleic acid chromatography.

The invention discloses a primer group for detecting respiratory tract microorganisms based on a nanopore sequencing method. The nucleotide sequences of the primer group are as shown in SEQ ID NO:1-20. The microorganisms are streptococcus pneumoniae, staphylococcus aureus (resisting to methicillin), klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, stenotrophomonas maltophilia, candida albicans, haemophilus influenzae, legionella pneumophila, enterococcus faecium, chlamydia psittaci, cryptococcus gattii, aspergillus fumigatus and pneumocystis jiroveci. According to the invention, sequencing optimization is carried out on different types of samples of the respiratory tract microorganisms, so that the detection method, the kit and the like are suitable for various typesof respiratory tract samples; and a targeted amplification method is adopted, so that the detection requirements of sputum, alveolar lavage and other sample types can be met. In addition, parallel sequencing can be performed, so that the flux of the detected samples is increased, the sequencing time is shortened, and the contradiction between the flux of detected pathogenic species and the cost and time is further relieved.

The invention relates to a 15-valence pneumococcus conjugate combined vaccine. The combination particularly contains 2-type and 12 F serotypes, has a wide immunization coverage rate and is used for preventing infectious diseases caused by pneumococcus. The combined vaccine further contains a 1-type serotype, a 3-type serotype, a 4-type serotype, a 5-type serotype, a 6A serotype, a 6B serotype, a 7F serotype, a 9V serotype, a 14-type serotype, a 18 C serotype, a 19 A serotype, a 19 F serotype and a 23 F serotype.

The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and / or PhtD, vaccines comprising the immunogenic compositions and their use in medicine.

Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or "PspC", different clades of PspC, isolated and / or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or of S. pneumoniae by detecting a nucleic acid molecule therefor in a sample such as by amplification and / or a polymerase chain reaction, vectors or plasmids which contain and / or express such nucleic acid molecles, e.g., in vitro or in vivo, immunological, immunogenic or vaccine compositions including at least one PspC and / or a portion thereof (such as at least one epitopic region of at least one PspC and / or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and / or a fragment thereof and / or at least one PspA and / or at least one epitopic region of at least one PspA and / or at least one polypeptide including at least one epitope of PspA. PspC or a fragment thereof, and thus a composition including PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as PspA. Thus, the invention further provides methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen which induces an immune response against Streptococcus pneumoniae. The combination allows a single dose for immunising against three separate causes of a common disease, namely bacterial meningitis.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The invention is directed to multivalent pneumococcal glycoconjugate compositions containing a newly emerging serotype of S. pneumonia, polysaccharide 24F, and their manufacture and use. The pneumococcal serotype 24F contains a polysaccharide repeating unit structure. The multivalent immunogenic composition comprises at least 25 S. pneumonia capsular polysaccharides selected from the serotypes 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20, 22F, 23B, 23F, 24F, 33F and 35B of S. pneumoniae preferably conjugated to carrier protein either directly or through a linker and a pharmaceutically acceptable carrier and / or adjuvant. The disclosure provides the capsular polysaccharide structure of serotype 24F to understand the polysaccharide before conjugation with carrier protein.

Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2i or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope. Compositions further include isolated nucleic acid molecules that encode the polypeptides of the invention, immunogenic compositions and vaccines comprising the disclosed polypeptides, and antibodies specific for these polypeptides.

The present invention provides a process improvement related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein. The serotype 35B polysaccharide-protein conjugate, prepared by the disclosed process, is, among other things, more immunogenic than similar conjugates made by prior art methods. S. pneumoniae serotype 35B polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccine compositions.

The invention relates to application of an L-rhamnose antibody in preparation of a drug for preventing and / or treating drug-resistant bacterial infection. The L-rhamnose antibody is used for specifically recognizing L-rhamnose, and the L-rhamnose antibody is a human source L-rhamnose natural antibody or a mouse source L-rhamnose monoclonal antibody; the drug-resistant bacteria particularly belong to drug-resistant bacteria of which the genome contains an L-rhamnose synthesis route. According to the application disclosed by the invention, L-rhamnose synthetic pathways exist in genomes of a considerable part of drug-resistant bacteria, so that L-rhamnose exists in polysaccharide structures on the surfaces of many drug-resistant bacteria, and L-rhamnose antibodies can recognize and be combined with the L-rhamnose structures on the surfaces of the drug-resistant bacteria; further, the compound has extremely strong inhibiting and killing capability on various drug-resistant bacteria including pseudomonas aeruginosa, escherichia coli and streptococcus pneumoniae, and has the advantages of broad spectrum and good killing effect.

The invention discloses a strain culture medicine favorable for preventing bacterial contamination. The culture medium comprises the following raw materials in parts by weight: 15 to 45 parts of jerusalem artichoke, 10 to 30 parts of codonopsis pilosula, 10 to 30 parts of medlar leaf, 20 to 80 parts of peptone, 15 to 55 parts of corn pulp, 10 to 35 parts of bran, 0.25 to 2.0 g / L of MgSO4, 2.0 to 12.0 g / L of NaCl, 0.8 to 3.0 g / L of K2HPO4, 0.1 to 0.3 g / L of ZnSO4, 0.01 to 0.08 g / L of FeSO4, 0.2 to 1.2 g / L of nicotinic acid, 3.5 to 8.5 g / L of adenine, 0.8 to 2.0 g / L of cysteine, 15 to 20 parts of agar and 1000 parts of water. The culture medium promotes obvious increment of proliferation rate of streptococcus pneumonia and is not liable to bacterial contamination.

A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.

The present invention provides proteins / genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.

Provided are a method and a kit for accurately and rapidly detecting ten types of targeting pneumonia bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus aureus. A set of primer pairs directed to their respective target regions contained in the DnaJ gene, etc., of the ten types of pneumonia causative bacteria is designed for the ten bacterial strains and used to amplify gene products. A set of bacterial strain-specific probe pairs is further designed for the ten bacterial strains such that the probe pairs hybridize with the amplification products via sequences in the respective target regions differing from the sequences hybridized by the set of primer pairs. A first probe-bound labeled high molecular carrier in which plural types of first probes for the pneumonia bacteria are bound to a labeled high molecular carrier and a solid-phase second probe-carrying developing support are used as the set of probe pairs to perform nucleic acid chromatography.

The invention belongs to the field of biological products, and discloses a streptococcus pneumoniae vaccine, which comprises SPD_0151 protein and an immunologic adjuvant, and the amino acid sequence of the SPD_ 0151 protein is SEQ ID NO.1. The invention also discloses a preparation method of the SPD_0151 protein, which comprises the following steps: inserting spd_0151 gene which contains no signalpeptide sequence into a recombinant plasmids, introducing the recombinant plasmids into expression bacteria, inducing expression, and purifying to obtain the SPD_0151 protein, wherein the sequence ofthe spd_0151 gene is shown as SEQ ID NO.2. The streptococcus pneumoniae vaccine has a good protection effect on challenge of streptococcus pneumoniae strains of different subtypes, and can effectively enhance the resistance to streptococcus pneumoniae.

The invention relates to a special diluent for detecting Streptococcus pneumoniae in urine samples. The diluent is composed of five components: borax, 1307Prill, ε-polylysine, C-reactive protein polyclonal antibody, and purified water. The content of each component is as follows: borax as component I content is 50mM ~ 100mM, 1307Prill as component II content is 0.5% ~ 1%, ε‑polylysine as component III content is 0.5% ~ 1%, C‑reaction The content of protein polyclonal antibody as component IV is 10ug / ml-20ug / ml, and the rest is purified water. The diluent mixed with the urine sample at a volume ratio of 1:9 can effectively inhibit the interference of the C-reactive protein in the urine sample on the detection results of Streptococcus pneumoniae, significantly improve the detection rate of Streptococcus pneumoniae, and play an important role in the accurate detection of urine Streptococcus pneumoniae in fluid samples is of great significance and has good clinical application value.

The invention discloses a primer-probe combination and detection kit for detecting new coronavirus and pneumonia pathogenic bacteria. A primer pair for detecting a new coronavirus ORF1ab gene is shown as SEQ ID NO: 1-2, and a probe is shown as SEQ ID NO: 3; a primer pair for detecting a new coronavirus N gene is shown as SEQ ID NO: 4-5, and a probe is shown as SEQ ID NO: 6; and a primer pair for detecting haemophilus influenzae is shown as SEQ ID NO: 7-8, and a probe is shown as SEQ ID NO: 9. A primer pair for detecting streptococcus pneumoniae is shown as SEQ ID NO: 10-11, and a probe is shown as SEQ ID NO: 12; a primer pair for detecting mycoplasma pneumoniae is shown as SEQ ID NO: 13-14, and a probe is shown as SEQ ID NO: 15; and a primer pair for detecting chlamydia pneumoniae is shown as SEQ ID NO: 16-17, and a probe is shown as SEQ ID NO: 18. The primers and the probes provided by the invention have good sensitivity and specificity, and can be efficiently applied to screening and triage of new coronavirus infection and community-acquired pneumonia infection by applying the primers and the probes to the detection kit.